The situation on antimicrobial agents and chemotherapy in 2002: Highlights of the 42nd ICAAC: 27-30 September 2002, San Diego, USA

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 6, 2002, Pages 691-697

  Giglione, Carmela ^a   Meinnel, Thierry ^a  

^a CNRS   (France)

Author keywords

Bioterrorism; Daptamycin; Deformylase; Horizontal transfer; Malaria; Quorum sensing; Resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL ENZYME; BAMBERMYCIN; BETA LACTAM ANTIBIOTIC; CHLOROQUINE; CLARITHROMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DIHYDROFOLATE REDUCTASE INHIBITOR; ERYTHROMYCIN; FANSIDAR; FOSMIDOMYCIN; FUSARIC ACID; KETOLIDE; LINEZOLID; MACROLIDE; METICILLIN; ORITAVANCIN; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; POLYPEPTIDE ANTIBIOTIC AGENT; PUROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; TEICOPLANIN; TELITHROMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIOLOGICAL WARFARE; CONFERENCE PAPER; DRUG DESIGN; DRUG MECHANISM; HORIZONTAL GENE TRANSFER; HUMAN; MALARIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; UNITED STATES;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIMALARIALS; BACTERIAL PROTEINS; BIOTERRORISM; CHILD; CLINICAL TRIALS; DISEASE TRANSMISSION, HORIZONTAL; DRUG DESIGN; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; HUMANS; INFECTION; INFECTION CONTROL; MALARIA; SOCIAL PROBLEMS; WORLD HEALTH;

EID: 0036931922     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.6.691     Document Type: Conference Paper

References (28)

1. WOOLHOUSE M: Population biology of emerging and re-emerging pathogens. Trends Microbiol (2002) 10(Suppl. 10):S3-S7.
2. JERNIGAN DB, RAGHUNATHAN PL, BELL BP et al.: Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. (2002) 8(10):1019-1028.
3. MOUREZ M, LACY DB, CUNNINGHAM K et al.: 2001: a year of major advances in anthrax toxin research. Trends Microbiol. (2002) 10(6):287-293.
4. KAISER J: 2003 budget: bioterrorism drives record NIH request. Science (2002) 295(5556):785.
5. KAISER J: NIH Director-Designate. Money, mission, management top Zerhouni's agenda. Science (2002) 296(5565):24-25.
6. FELMINGHAM D: Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective resistant organism tracking and epidemiology for the ketolide telithromycin. J. Infect. (2002) 44(Suppl.):A3-A10.
7. SMITH DL, HARRIS AD, JOHNSON JA, SILBERGELD EK, MORRIS JG Jr: Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria. Proc. Natl. Acad. Sci. USA (2002) 99(9):6434-6439.
8. LIM D, STRYNADKA NC: Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. (2002) 9(11):870-876.
9. NOBLE WC, VIRANI Z, CREE RG: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. (1992) 72(2):195-198.
10. NO AUTHORS LISTED: Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(26):565-567.
11. TRIEU-CUOT P, GERBAUD G, LAMBERT T, COURVALIN P: In vivo transfer of genetic information between Gram-positive and Gram-negative bacteria. EMBO J. (1985) 4(13A):3583-3587.
12. MCKEEGAN K, BORGES-WALMSLEY M, WALMSLEY A: Microbial and vital drug resistance mechanisms. Trends Microbial. (2002) 10(Suppl. 10):S8-S14.
13. GREEN DW. The bacterial cell wall as a source of antibacterial targcts. Expert Opin. Ther. Targets (2002) 6(1):1-19.
14. FERBER D: Infectious disease. New weapons in the battle of the bugs. Science (2002) 295(5554):433-434.
15. GIGLIONE C, PIERRE M, MEINNEL T: Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol. (2000) 36(6):1197-1205.
16. YUAN Z, TRIAS J, WHITE RJ: Deformylase as a novel antibacterial target. Drug Discov. Today (2001) 6(18):954-961.
17. GIGLIONE C, MEINNEL T: Resistance to anti-peptide deformylase drugs. Expert Opin. Ther Targets (2001) 5(3):415-418.
18. BUSH K, JACOBY GA, MEDEIROS AA: A functional classification scheme for betalactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. (1995) 39(6):1211-1233.
19. PAYNE DJ, DU W, BATESON JH: betalactamase epidemiology and the utility of established and novel beta-lactamase inhibitors. Expert Opin. Investig. Drugs (2000) 9(2):247-261.
20. HILGERS MT, LUDWIG ML: Crystal structure of the quorum-sensing protein LuxS reveals a catalytic metal site. Proc. Natl. Acad, Sci. USA (2001) 98(20):11169-11174.
21. WILLIAMS P: Quorum sensing: an emerging target for antibacterial chemotherapy? Expert Opin. Ther. Targets, (2002) 6(3):257-274.
22. PENNISI E: Malaria research. Parasite genome sequenced, scrutinized. Science (2002) 298(5591):33-34.
23. GIGLIONE C, MEINNEL T: Peptide deformylase as an emerging target for antiparasitic agents. Emerg. Ther. Targets (2001) 5(1):41-57.
24. SACHS JD: A new global effort to control malaria. Science (2002) 298(5591):122-124.
25. PARKINSON T: The impact of genomics on anti-infectives drug discovery and development. Trends Microbiol. (2002) 10(Suppl. 10):S22-S26.
26. HANEY SA, ALKSNE LE, DUNMAN PM, MURPHY E, PROJAN SJ: Genomics in anti-infective drug discovery getting to endgame. Curr. Pharm. Des. (2002) 8(13):1099-1118.
27. SCHMID M: Structural proteomics: the potential of high-throughput structure determination. Trends Microbiol. (2002) 10(Suppl. 10):S27-S31.
28. GUILLOTEAU JP, MATHIEU M, GIGLIONE C et al.: The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. Mol. Biol. (2002) 320(5):951-962.